No results for ‘’
NSE: undefined BSE: undefined
â‚ą-
(-%)
Sat, 12 Sept 2026, 08:36 pm
Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (6.7x coverage).
- Dividends after 3 years are expected to be well covered by earnings (5.8x coverage).
- J. B. Chemicals & Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- J. B. Chemicals & Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- J. B. Chemicals & Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- J. B. Chemicals & Pharmaceuticals's earnings are expected to exceed the low risk growth rate next year.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in J. B. Chemicals & Pharmaceuticals's performance (ROE) is expected over the next 3 years.
- J. B. Chemicals & Pharmaceuticals's revenue growth is expected to exceed the India market average.
- Cash flow for J. B. Chemicals & Pharmaceuticals is expected to increase but not above the 50% threshold in 2 years time.
- J. B. Chemicals & Pharmaceuticals's earnings are expected to grow by 12.8% yearly, however this is not considered high growth (20% yearly).
- J. B. Chemicals & Pharmaceuticals's earnings growth is positive but not above the India market average.
- J. B. Chemicals & Pharmaceuticals's net income is expected to increase but not above the 50% threshold in 2 years time.
- J. B. Chemicals & Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- J. B. Chemicals & Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.
- J. B. Chemicals & Pharmaceuticals's revenue is expected to grow by 12.1% yearly, however this is not considered high growth (20% yearly).
health
- J. B. Chemicals & Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- J. B. Chemicals & Pharmaceuticals is profitable, therefore cash runway is not a concern.
- J. B. Chemicals & Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (583.5%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 25.9x debt.
- J. B. Chemicals & Pharmaceuticals's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (11.8% vs 3% today).
- J. B. Chemicals & Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
- J. B. Chemicals & Pharmaceuticals's level of debt (3%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the J. B. Chemicals & Pharmaceuticals board of directors is about average.
- Jyotindra's compensation has been consistent with company performance over the past year, both up more than 20%.
- Jyotindra's remuneration is higher than average for companies of similar size in India.
misc
- J. B. Chemicals & Pharmaceuticals has significant price volatility in the past 3 months.
past
- J. B. Chemicals & Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (49.3% vs 14.3%)
- J. B. Chemicals & Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
- J. B. Chemicals & Pharmaceuticals used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- J. B. Chemicals & Pharmaceuticals has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- J. B. Chemicals & Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (49.3% vs 22.7%).
- J. B. Chemicals & Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- JBCHEPHARM outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- JBCHEPHARM outperformed the Market in India which returned -14.5% over the past year.
- NSEI:JBCHEPHARM is up 13.3% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:JBCHEPHARM is up 13.3% outperforming the market in India which returned 8% over the past month.
- J. B. Chemicals & Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- J. B. Chemicals & Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- J. B. Chemicals & Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- J. B. Chemicals & Pharmaceuticals is poor value based on expected growth next year.
- J. B. Chemicals & Pharmaceuticals is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- J. B. Chemicals & Pharmaceuticals is overvalued based on earnings compared to the India market.